Additional Ventures

What Additional Ventures does

Additional Ventures is a nonprofit biomedical research foundation founded in 2020 and headquartered in Palo Alto, California. The organization is the largest dedicated funder of single ventricle congenital heart disease research, having committed over $95M since inception to support 200+ studies and 125+ publications. It operates a portfolio of complementary grant programs: the Single Ventricle Research Fund (SVRF) supports foundational research with two tracks up to $600K; the Catalyst to Independence Award supports early-career transitions with up to $1M over five years; the Expansion Award provides $50K additions to existing projects; the AHA/AV Collaborative Sciences Awards fund multidisciplinary teams with up to $2.25M; and the Translational Accelerator (including the AV-CTIP Device Innovation Award) supports device and therapeutic translation with up to $1M in milestone-driven funding. The foundation also executes the Single Ventricle SOURCE study, a whole-genome sequencing effort targeting 5,000 patients and 5,000 family members to build the world's largest genetic database for the disease.

The organization's business model is philanthropic: revenue is derived from charitable contributions and deployed via competitive grant cycles managed through the ProposalCentral portal, with all award applications free to submit. Additional Ventures does not sell products or services; it functions as an agile research catalyst. It serves three principal constituencies: academic and clinical researchers (principal investigators, postdocs, and clinical investigators at institutions such as Stanford, Boston Children's Hospital, CHOP, Yale, Cornell, Gladstone Institutes, and Imperial College London), single ventricle patients and their families, and pediatric cardiologists and cardiac surgeons. GTM motion is community-led, centered on convening researchers via the annual Single Ventricle Investigator Meeting (SVIM), speaker series, and direct outreach through the foundation's website and email newsletters.

The organization supplements its grant-making with strategic direct investments in translational device companies (FluidForm, StarBP, Renata Medical), co-branded funding partnerships with the American Heart Association, and spoke membership in the ARPA-H Investor Catalyst Hub. CEO Kirstie Keller leads a lean 1-10 person operating team. Geographic reach spans the United States, United Kingdom, Switzerland, Belgium, Italy, and Canada. Founding date is 2020.

Name

Additional Ventures

Legal name

Additional Ventures

Website

https://additionalventures.org

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Additional Ventures is a nonprofit biomedical research foundation founded in 2020 that funds single ventricle heart disease research through grant programs and the SOURCE genetic study. It serves academic researchers, pediatric clinicians, and patient families by deploying philanthropic capital across basic, translational, and clinical science.

Ownership category

akta.pro rank

Product category

Biomedical Research Funding

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Research & Science Grantmaking Foundations (BPAGAKAI), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Biomedical research funding
• Congenital heart disease
• Research grant programs
• Translational research support
• Nonprofit research foundation

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Philanthropic Funding / Donations: Additional Ventures is a nonprofit organization funded through charitable donations and grants. Revenue is derived from philanthropic contributions used to fund single ventricle research programs and operations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Additional Ventures operates as a nonprofit biomedical research foundation that funds and accelerates single ventricle heart disease research through competitive grant programs (SVRF, Catalyst to Independence, Expansion Awards, AHA/AV Collaborative Sciences Awards) and strategic translational investments. It runs the world's largest single ventricle genetic study enrolling 10,000+ participants for whole genome sequencing, and operates the Translational Accelerator program to bridge the valley of death between laboratory discoveries and clinical application.

Product overview

Additional Ventures is a nonprofit biomedical research organization (not a traditional software/product company) dedicated to curing single ventricle heart disease through transformative research funding and strategic investments. The organization operates a portfolio of complementary research award programs: the flagship Single Ventricle Research Fund (SVRF) supports foundational research studies; the Catalyst to Independence Award and Career Development track support early-career scientists transitioning to independence; the Expansion Award enables teams to expand existing funded projects; the AHA/AV Collaborative Sciences Awards fund multidisciplinary team science; and the Translational Accelerator (including the AV-CTIP Device Innovation Award) supports device and therapeutic translation. The Single Ventricle SOURCE study represents their major observational research initiative to build a comprehensive genetic database. Together, these programs form a coordinated ecosystem designed to advance single ventricle research from basic discovery through clinical translation.

Differentiator

Problem solved

Functional benefit

Brands

• Single Ventricle Research Fund (SVRF): Annual research award program supporting foundational studies aimed at improving outcomes for individuals with single ventricle heart disease.
• Catalyst to Independence Award
• Expansion Award
• AHA/AV Collaborative Sciences Awards
• Translational Accelerator
• Single Ventricle SOURCE

Products and services

• Single Ventricle Research Fund (SVRF) Flagship annual research award program supporting foundational studies aimed at improving outcomes for individuals with single ventricle heart disease. Offers two tracks: Independent Investigator (up to $600,000) and Career Development (up to $300,000), spanning three years. Intended for principal investigators conducting single ventricle research at academic institutions and research hospitals.
• Catalyst to Independence Award Transition award supporting exceptional early career scientists during the final years of mentored postdoctoral research through transition to independent faculty. Provides up to $1M over up to 5 years, including research funds, career coaching, and networking opportunities. Targets postdoctoral fellows within the single ventricle research field.
• Expansion Award One-time grant of $50,000 enabling teams to add new single ventricle-focused approaches to their currently funded work. Open to both new and established investigators within the single ventricle research community with an efficient submission and award process.
• AHA/AV Collaborative Sciences Awards Multidisciplinary, multi-institutional research award program in partnership with the American Heart Association supporting teams addressing key knowledge gaps in clinical sequelae of single ventricle heart disease. Awards up to $2.25M direct costs over 3 years.
• AV-CTIP Device Innovation Award Partnership award with the Consortium for Technology & Innovation in Pediatrics (CTIP) advancing early-stage device concepts purpose-built for single ventricle patients. Provides up to $1M in milestone-driven funding over approximately 3 years with access to advising, services, and support.
• Single Ventricle SOURCE The largest and most ambitious study of its kind, enrolling at least 5,000 single ventricle patients and 5,000 family members to collect medical histories and genetic data through whole genome sequencing. Creates the world's largest genetic database for single ventricle heart disease with IRB approval.
• Translational Accelerator Groundbreaking program designed to close resource gaps that stall translational progress in single ventricle science by providing funding and strategic expertise. Addresses gaps in funding, mentorship, and regulatory readiness to help researchers bridge the valley of death in single ventricle science.
• Life Sciences Research Foundation Postdoctoral Fellowship Partnership with the Life Sciences Research Foundation supporting outstanding postdoctoral fellows making advances in basic science. Provides $67,000 per fellow per year for three years for applicants within 5 years of receiving their PhD or MD degree.

Quantifiable outcome

• Over $95M in research funding deployed since 2020
• +4 more outcomes

Named customers13 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and flagship.

• Every 100th Heart CoalitioncoreStrategic or Co-development Partner · 3 February 2026National coalition of six patient advocacy organizations including American Heart Association and Adult Congenital Heart Association, dedicated to elevating congenital heart disease as a federal health policy priority.
• Consortium for Technology & Innovation in Pediatrics (CTIP)flagshipStrategic or Co-development Partner · 3 September 2025Partnership to create AV-CTIP Device Innovation Award advancing early-stage device concepts purpose-built for single ventricle patients. CTIP provides technical resources, coaching, strategic connections, and access to consulting and service providers for device development and commercialization.
• Alliance for Pediatric Device Innovation (APDI)coreStrategic or Co-development Partner · 24 October 2024Partnership through APDI, a nonprofit consortium led by Children's National Hospital and funded through FDA, for 'Make Your Medical Device Pitch for Kids!' competition supporting pediatric cardiology device innovation.
• ARPA-H Investor Catalyst HubcoreStrategic or Co-development Partner · 4 September 2024Additional Ventures selected as spoke member for the Investor Catalyst Hub, a regional hub of ARPANET-H nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Hub managed by VentureWell based in Greater Boston area.
• American Heart Association (AHA)flagshipStrategic or Co-development Partner · 9 August 2024Joint $13.2M Collaborative Sciences Awards in Single Ventricle Heart Disease program supporting multidisciplinary, multi-institutional research teams addressing key knowledge gaps in clinical sequelae of single ventricle heart disease. Five teams selected covering Fontan Associated Liver Disease, arrhythmias, neurodevelopmental disorders, and T-cell dysfunction.
• Life Sciences Research FoundationcoreStrategic or Co-development Partner · 1 January 2023Partnership to support outstanding postdoctoral fellows making waves in basic science and advancing fundamental knowledge in single ventricle research. Awards $67,000 per fellow per year for three years.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Cystic Fibrosis Foundation: Disease-specific research foundation with a mature model combining investigator grants, translational funding, and venture-style investments in therapeutic developers. Compares directly to AV's blended grantmaking-plus-equity approach, scaled to a much larger disease.
• Parent Project Muscular Dystrophy: Patient-driven nonprofit funding Duchenne muscular dystrophy research across basic, translational, and clinical stages. Mirrors AV's pipeline approach with grant programs, a venture-style subsidiary, and strong community-anchored identity.
• Conquering CHD: Patient advocacy organization for congenital heart disease including single ventricle patients. AV partners with similar advocacy-style organizations; comparable as a CHD-focused nonprofit with patient and family support orientation.
• Children's Heart Foundation: U.S. nonprofit that funds congenital heart disease research including single ventricle defects. Direct mission and disease-area overlap with Additional Ventures, serving as the closest grassroots analog among CHDs.
• St. Baldrick's Foundation: Pediatric cancer research foundation funding young investigators and translational projects. Shares AV's disease-focused, donor-funded, multi-program model aimed at hard-to-treat pediatric conditions.
• Alpha-1 Foundation: Disease-specific nonprofit funding alpha-1 antitrypsin deficiency research, including translational grants and investment arms. Demonstrates AV's playbook of combining research grants with catalytic investments in therapeutic companies.

Broad incumbents

• Doris Duke Charitable Foundation (Medical Research): Major medical research grantmaking foundation supporting clinical research and early-career physician-scientists. Overlaps with AV on translational research and career-development tracks but at broader and larger scale.
• American Heart Association: Largest U.S. cardiovascular research nonprofit and AV's flagship partner through the Collaborative Sciences Awards. Operates much broader research scope but is the dominant incumbent funder in cardiac research that AV researchers also apply to.
• Leukemia & Lymphoma Society: Large disease-focused nonprofit combining traditional grants, therapy Acceleration Program (venture-style funding), and patient services. A scaled-up template for the translational-plus-grantmaking model AV is building.
• Howard Hughes Medical Institute: Large biomedical research organization funding basic discovery through investigator and early-career programs (e.g., HHMI Hanna Gray). Comparable career-development funding mechanism to AV's Catalyst to Independence Award but at much greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/pulse/bridging-valley-death-single-ventricle-translational-gxtlf
• Xx.com/additionalvent

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Additional Ventures